title: Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography.
abstract: Nicotine addiction is a major public health problem, resulting in primary glutamatergic dysfunction. We measured the glutamate receptor binding in the human brain and provided direct evidence for the abnormal glutamate system in smokers. Because antagonism of the metabotropic glutamate receptor 5 (mGluR5) reduced nicotine self-administration in rats and mice, mGluR5 is suggested to be involved in nicotine addiction. mGluR5 receptor binding specifically to an allosteric site was observed by using positron emission tomography with [(11)C]ABP688. We found a marked global reduction (20.6%; P < 0.0001) in the mGluR5 distribution volume ratio (DVR) in the gray matter of 14 smokers. The most prominent reductions were found in the bilateral medial orbitofrontal cortex. Compared with 14 nonsmokers, 14 ex-smokers had global reductions in the average gray matter mGluR5 DVR (11.5%; P < 0.005), and there was a significant difference in average gray matter mGluR5 DVR between smokers and ex-smokers (9.2%; P < 0.01). Clinical variables reflecting current nicotine consumption, dependence and abstinence were not correlated with mGluR5 DVR. This decrease in mGluR5 receptor binding may be an adaptation to chronic increases in glutamate induced by chronic nicotine administration, and the decreased down-regulation seen in the ex-smokers could be due to incomplete recovery of the receptors, especially because the ex-smokers were abstinent for only 25 wk on average. These results encourage the development and testing of drugs against addiction that directly target the glutamatergic system.
authors.affiliation: Psychiatric University Hospital,  University of Bern, 3000 Bern 60,  Switzerland.
authors.forename: Funda
authors.initials: F
authors.lastname: Akkus
authors.forename: Simon M
authors.initials: SM
authors.lastname: Ametamey
authors.forename: Valerie
authors.initials: V
authors.lastname: Treyer
authors.forename: Cyrill
authors.initials: C
authors.lastname: Burger
authors.forename: Anass
authors.initials: A
authors.lastname: Johayem
authors.forename: Daniel
authors.initials: D
authors.lastname: Umbricht
authors.forename: Baltazar
authors.initials: B
authors.lastname: Gomez Mancilla
authors.forename: Judit
authors.initials: J
authors.lastname: Sovago
authors.forename: Alfred
authors.initials: A
authors.lastname: Buck
authors.forename: Gregor
authors.initials: G
authors.lastname: Hasler
mesh_terms: D000495:Allosteric Site / Q000502:physiology*; D001921:Brain / Q000378:metabolism*; D002250:Carbon Radioisotopes; D006801:Humans; D010091:Oximes; D049268:Positron-Emission Tomography; D011725:Pyridines; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate / Q000378:metabolism*; D012907:Smoking / Q000378:metabolism*; D013557:Switzerland; D014029:Tobacco Use Disorder / Q000378:metabolism*
chemical_list: C510950:3-(6-methylpyridin-2-ylethynyl)cyclohex-2-enone-O-methyloxime; D002250:Carbon Radioisotopes; C578935:GRM5 protein, human; C578936:Grm5 protein, mouse; C578937:Grm5 protein, rat; D010091:Oximes; D011725:Pyridines; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate